File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Synthesis of Injectable Shear-Thinning Biomaterials of Various Compositions of Gelatin and Synthetic Silicate Nanoplatelet

TitleSynthesis of Injectable Shear-Thinning Biomaterials of Various Compositions of Gelatin and Synthetic Silicate Nanoplatelet
Authors
Keywordsinjectability
laponite
rheology
shear-thinning biomaterial
gelatin
Issue Date2020
Citation
Biotechnology Journal, 2020, v. 15, n. 8, article no. 1900456 How to Cite?
Abstract© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Injectable shear-thinning biomaterials (iSTBs) have great potential for in situ tissue regeneration through minimally invasive therapeutics. Previously, an iSTB was developed by combining gelatin with synthetic silicate nanoplatelets (SNPs) for potential application to hemostasis and endovascular embolization. Hence, iSTBs are synthesized by varying compositions of gelatin and SNPs to navigate their material, mechanical, rheological, and bioactive properties. All compositions (each component percentage; 1.5–4.5%/total solid ranges; 3–9%) tested are injectable through both 5 Fr general catheter and 2.4 Fr microcatheter by manual pressure. In the results, an increase in gelatin contents causes decrease in swellability, increase in freeze-dried hydrogel scaffold porosity, increase in degradability and injection force during iSTB fabrication. Meanwhile, the amount of SNPs in composite hydrogels is mainly required to decrease degradability and increase shear thinning properties of iSTB. Finally, in vitro and in vivo biocompatibility tests show that the 1.5–4.5% range gelatin–SNP iSTBs are not toxic to the cells and animals. All results demonstrate that the iSTB can be modulated with specific properties for unmet clinical needs. Understanding of mechanical and biological consequences of the changing gelatin–SNP ratios through this study will shed light on the biomedical applications of iSTB on specific diseases.
Persistent Identifierhttp://hdl.handle.net/10722/295421
ISSN
2020 Impact Factor: 4.677
2015 SCImago Journal Rankings: 1.185
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorXue, Chengbin-
dc.contributor.authorXie, Huifang-
dc.contributor.authorEichenbaum, James-
dc.contributor.authorChen, Yi-
dc.contributor.authorWang, Yonggang-
dc.contributor.authorvan den Dolder, Floor W.-
dc.contributor.authorLee, Junmin-
dc.contributor.authorLee, Kang Ju-
dc.contributor.authorZhang, Shiming-
dc.contributor.authorSun, Wujin-
dc.contributor.authorSheikhi, Amir-
dc.contributor.authorAhadian, Samad-
dc.contributor.authorAshammakhi, Nureddin-
dc.contributor.authorDokmeci, Mehmet R.-
dc.contributor.authorKim, Han Jun-
dc.contributor.authorKhademhosseini, Ali-
dc.date.accessioned2021-01-18T15:46:50Z-
dc.date.available2021-01-18T15:46:50Z-
dc.date.issued2020-
dc.identifier.citationBiotechnology Journal, 2020, v. 15, n. 8, article no. 1900456-
dc.identifier.issn1860-6768-
dc.identifier.urihttp://hdl.handle.net/10722/295421-
dc.description.abstract© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Injectable shear-thinning biomaterials (iSTBs) have great potential for in situ tissue regeneration through minimally invasive therapeutics. Previously, an iSTB was developed by combining gelatin with synthetic silicate nanoplatelets (SNPs) for potential application to hemostasis and endovascular embolization. Hence, iSTBs are synthesized by varying compositions of gelatin and SNPs to navigate their material, mechanical, rheological, and bioactive properties. All compositions (each component percentage; 1.5–4.5%/total solid ranges; 3–9%) tested are injectable through both 5 Fr general catheter and 2.4 Fr microcatheter by manual pressure. In the results, an increase in gelatin contents causes decrease in swellability, increase in freeze-dried hydrogel scaffold porosity, increase in degradability and injection force during iSTB fabrication. Meanwhile, the amount of SNPs in composite hydrogels is mainly required to decrease degradability and increase shear thinning properties of iSTB. Finally, in vitro and in vivo biocompatibility tests show that the 1.5–4.5% range gelatin–SNP iSTBs are not toxic to the cells and animals. All results demonstrate that the iSTB can be modulated with specific properties for unmet clinical needs. Understanding of mechanical and biological consequences of the changing gelatin–SNP ratios through this study will shed light on the biomedical applications of iSTB on specific diseases.-
dc.languageeng-
dc.relation.ispartofBiotechnology Journal-
dc.subjectinjectability-
dc.subjectlaponite-
dc.subjectrheology-
dc.subjectshear-thinning biomaterial-
dc.subjectgelatin-
dc.titleSynthesis of Injectable Shear-Thinning Biomaterials of Various Compositions of Gelatin and Synthetic Silicate Nanoplatelet-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/biot.201900456-
dc.identifier.pmid32107862-
dc.identifier.pmcidPMC7415533-
dc.identifier.scopuseid_2-s2.0-85081737216-
dc.identifier.volume15-
dc.identifier.issue8-
dc.identifier.spagearticle no. 1900456-
dc.identifier.epagearticle no. 1900456-
dc.identifier.eissn1860-7314-
dc.identifier.isiWOS:000559735900011-
dc.identifier.issnl1860-6768-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats